Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

To join this study, you must be 18 years or older and able to give your clear agreement to take part. You must also have advanced or metastatic kidney cancer and be about to start treatment with cabozantinib, either on its own or combined with nivolumab. This would be your first treatment for this type of cancer, and the decision to use these medicines must have already been made by your doctor based on standard NHS guidelines.

There are also some reasons why you might not be able to join. For example, if you are currently taking part in another medical study where new treatments are being tested, or if you have been in such a study within the last three months, you wouldn't be able to participate. You also can't join if you've been part of this specific study before.

Both men and women can take part, as long as they meet the age and health requirements.

If you join this study, you won't be given a new or experimental treatment. Instead, your doctors will simply observe and record information about your standard treatment with cabozantinib (alone or with nivolumab) as you receive it during your regular clinic visits. This means your appointments, tests, and medications will be exactly what your doctor would normally recommend for your condition. The researchers will collect details on how well the treatment is working for you and any side effects you might experience. There are no additional study visits or extra procedures beyond what is already planned for your care. The total duration of your participation will depend on how long your doctor determines you should continue with this treatment.